The November issue of The American Journal of Gastroenterology features several articles examining the association between common conditions or treatments and the risk for disease development, including a study on the association between higher body mass index and increased risk for early-onset colorectal cancer, and a population study on proton pump inhibitors and all-cause mortality.
The August issue of The American Journal of Gastroenterology includes clinical discussions of diet-associated NAFLD risk and increased risk of mortality from COVID-19 among PPI users. In addition, this issue features clinical research and reviews on IBS, gender barriers for CRC screening, hepatitis C, eosinophilic esophagitis, and more.
The June issue of AJG includes articles on the effectiveness of OTC therapies and green kiwifruit as a dietary therapy for chronic constipation, as well as new ACG Guidelines on the Prevention, Diagnosis, and Treatment of C. difficile infections, and more.
Findings from an online survey of more than 53,000 American adults suggest that using heartburn medications known as proton pump inhibitors (PPIs) once or twice daily significantly increases the odds of a positive test for COVID-19 compared to those who do not take PPIs. This research appeared online July 7, 2020 in pre-print format in The American Journal of Gastroenterology.
Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect: impairment of breast cancer survivors’ memory and concentration.
Proton Pump Inhibitors (PPIs) — such as Prilosec, Protonix and Nexium, have long been one of the most prescribed medications in the country to aid in the reduction of stomach acid. f
A study published today in The New England Journal of Medicine found that in patients seen for heartburn unresponsive to treatment with Proton Pump Inhibitors (PPIs), an extensive, systematic workup revealed truly PPI-refractory and reflux-related heartburn in only a minority of cases. In other words, most patients with heartburn unrelieved by PPIs did not have gastroesophageal reflux disease (GERD) causing the symptom. Furthermore, for the selected subgroup identified as having reflux-related, PPI-refractory heartburn, surgery that corrects reflux was significantly superior (67% success rate) to continued medical therapy (28% success rate).